Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer

Endometrial cancer stands as the predominant gynecological malignancy in developed nations. For advanced or recurrent disease, paclitaxel-based chemotherapy is the standard front-line therapy. However, paclitaxel resistance eternally develops. Based on the high prevalence of phosphatidylinositol-4,5...

Full description

Bibliographic Details
Main Authors:	Yeong Gyu Jeong, Nar Bahadur Katuwal, Min Sil Kang, Mithun Ghosh, Sa Deok Hong, Seong Min Park, Seul-Gi Kim, Tae Hoen Kim, Yong Wha Moon
Format:	Article
Language:	English
Published:	MDPI AG 2023-10-01
Series:	Cancers
Subjects:	chemotherapy PI3K pathway endometrial cancer drug resistance paclitaxel resistance eribulin
Online Access:	https://www.mdpi.com/2072-6694/15/19/4887

Similar Items

Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells
by: Petra J. Pederson, et al.
Published: (2021-06-01)

Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms
by: Hugo Passos Vicari, et al.
Published: (2022-12-01)

Systematic Analysis of Genetic and Pathway Determinants of Eribulin Sensitivity across 100 Human Cancer Cell Lines from the Cancer Cell Line Encyclopedia (CCLE)
by: Pallavi Sachdev, et al.
Published: (2022-09-01)

Efficacy of Eribulin in Soft Tissue Sarcomas
by: Edward Phillips, et al.
Published: (2022-03-01)

Eribulin drug review
by: Nishitha Shetty, et al.
Published: (2014-01-01)

Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators
by: Kenichi Inoue, et al.
Published: (2018-06-01)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01)

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
by: Ana López González, et al.
Published: (2022-11-01)

Eribulin and Confusion: A Previously Unknown Drug Side-Effect
by: Abu Baker Sheikh, et al.
Published: (2020-06-01)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
by: Sonam Mittal, et al.
Published: (2023-09-01)

Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
by: Vera A Gorbunova, et al.
Published: (2019-03-01)

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
by: Ji-Yeon Kim, et al.
Published: (2019-05-01)

Drugs That Changed Society: Microtubule-Targeting Agents Belonging to Taxanoids, Macrolides and Non-Ribosomal Peptides
by: Søren Brøgger Christensen
Published: (2022-09-01)

Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving
by: E V Artamonova
Published: (2017-09-01)

Stathmin dynamics modulate the activity of eribulin in breast cancer cells
by: Mikihiro Yoshie, et al.
Published: (2021-08-01)

Eribulin alongwith capecitabine in relapsed carcinoma breast- a retrospective single-Institutional study.
by: Soumita Poddar, et al.
Published: (2023-08-01)

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
by: L V Bolotina, et al.
Published: (2016-09-01)

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas
by: María López-Álvarez, et al.
Published: (2022-12-01)

Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
by: Nar Bahadur Katuwal, et al.
Published: (2023-11-01)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
by: Renaud Sabatier, et al.
Published: (2021-03-01)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
by: I V Kolyadina, et al.
Published: (2018-09-01)

Stathmin expression alters the antiproliferative effect of eribulin in leiomyosarcoma cells
by: Mana Azumi, et al.
Published: (2022-12-01)

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
by: Min Ho Park, et al.
Published: (2020-12-01)

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
by: Elena I. Kovalenko, et al.
Published: (2020-05-01)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
by: Sakura Iizumi, et al.
Published: (2017-12-01)

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma
by: Alessandro De Vita, et al.
Published: (2016-12-01)

Multifarious targets beyond microtubules—role of eribulin in cancer therapy
by: Priya Seshadri, et al.
Published: (2021-12-01)

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
by: Irina V. Kolyadina, et al.
Published: (2021-05-01)

Eribulin in Cancer Treatment
by: Umang Swami, et al.
Published: (2015-08-01)

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study
by: E. I. Kovalenko, et al.
Published: (2021-12-01)

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
by: Jean-David Fumet, et al.
Published: (2018-08-01)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
by: Tsutomu Iwasa, et al.
Published: (2019-10-01)

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
by: Tremblay G, et al.
Published: (2016-09-01)

The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience
by: Irina V Kolyadina, et al.
Published: (2019-06-01)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
by: Hyemi Ko, et al.
Published: (2022-04-01)

Eribulin mesylate exerts antitumor effects via CD103
by: Kazumasa Oya, et al.
Published: (2023-12-01)

Therapeutic efficacy of a four-year treatment with eribulin in a patient with uterine leiomyosarcoma: A case report
by: Motoki Matsuura, et al.
Published: (2023-06-01)

Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types
by: Tamami Morisaki, et al.
Published: (2021-11-01)

Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin
by: Meng-Xia Su, et al.
Published: (2024-02-01)

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin
by: Bahram Sharif-Askari, et al.
Published: (2023-03-01)